AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines, reported Bloomberg. The oral GLP-1 drug resulted in patients losing an average of 5.8% of their body weight over four weeks in a small, early study, the report noted. Astra also presented early data on two other obesity drugs on Monday – a drug targeting the hormone amylin and an injectable GLP-1 – and noted that all three obesity assets are moving to mid-stage trials and were “highly competitive,” according to Bloomberg, citing Sharon Barr, executive vice-president of biopharmaceuticals R&D. The obesity medicines market has so far been dominated by Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound, noted Bloomberg, which also points out that Viking Therapeutics (VKTX) also presented data on its experimental pill at the conference and that Lilly and Novo also have pills for weight loss in the works.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- AstraZeneca reports China President currently under investigation
- AstraZeneca’s Fasenra approved in EU for EGPA
- Eccogene receives milestone payment of $60M from AstraZeneca
- CytoSorbents announces FDA has accepted De Novo medical device application